Literature DB >> 32671987

Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.

Helga Bergholtz1,2, Surendra Kumar1, Fredrik Wärnberg3,4, Torben Lüders2,5, Vessela Kristensen1,2,5, Therese Sørlie1,2.   

Abstract

BACKGROUND: Ductal carcinoma in situ (DCIS) comprises a diverse group of preinvasive lesions in the breast and poses a considerable clinical challenge due to lack of markers of progression. Genomic alterations are to a large extent similar in DCIS and invasive carcinomas, although differences in copy number aberrations, gene expression patterns, and mutations exist. In mixed tumors with synchronous invasive breast cancer (IBC) and DCIS, it is still unclear to what extent invasive tumor cells are directly derived from the DCIS cells. AIM: Our aim was to compare cancer-relevant mutation profiles of different cellular compartments in mixed DCIS/IBC and pure DCIS tumors. METHODS AND
RESULTS: We performed targeted sequencing of 50 oncogenes in microdissected tissue from three different epithelial cell compartments (in situ, invasive, and normal adjacent epithelium) from 26 mixed breast carcinomas. In total, 44 tissue samples (19 invasive, 16 in situ, 9 normal) were subjected to sequencing using the Ion Torrent platform and the AmpliSeq Cancer Hotspot Panel v2. For comparison, 10 additional, pure DCIS lesions were sequenced. Across all mixed samples, we detected 23 variants previously described in cancer. The most commonly affected genes were TP53, PIK3CA, and ERBB2. The PIK3CA:p.H1047R variant was found in nine samples from six patients. Most variants detected in invasive compartments were also found in the corresponding in situ cell compartment indicating a clonal relationship between the tumor stages. A lower frequency of variants were observed in pure DCIS lesions.
CONCLUSION: Similar mutation profiles between in situ and invasive cell compartments indicate a similar origin of the two tumor stages in mixed breast tumors. The lower number of potential driver variants found in pure DCIS compared with the in situ cell compartments of mixed tumors may imply that pure DCIS is captured earlier in the path of progression to invasive disease.
© 2020 The Authors. Cancer Reports published by Wiley Periodicals LLC.

Entities:  

Keywords:  DCIS; breast tumor progression; invasive breast cancer; mutations; targeted sequencing

Year:  2020        PMID: 32671987      PMCID: PMC7941529          DOI: 10.1002/cnr2.1248

Source DB:  PubMed          Journal:  Cancer Rep (Hoboken)        ISSN: 2573-8348


  30 in total

1.  Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?

Authors:  Mario Casales Schorr; José Luiz Pedrini; Ricardo Francalacci Savaris; Cláudio Galleano Zettler
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-01

2.  PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.

Authors:  Marie Colombe Agahozo; Anieta M Sieuwerts; S Charlane Doebar; Esther I Verhoef; Corine M Beaufort; Kirsten Ruigrok-Ritstier; Vanja de Weerd; Hein F B M Sleddens; Winand N M Dinjens; John W M Martens; Carolien H M van Deurzen
Journal:  Endocr Relat Cancer       Date:  2019-05       Impact factor: 5.678

3.  PIK3CA mutations in in situ and invasive breast carcinomas.

Authors:  Alexander Miron; Maria Varadi; Daniel Carrasco; Hailun Li; Lauren Luongo; Hee Jung Kim; So Yeon Park; Eun Yoon Cho; Gretchen Lewis; Sarah Kehoe; J Dirk Iglehart; Deborah Dillon; D Craig Allred; Laura Macconaill; Rebecca Gelman; Kornelia Polyak
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

4.  Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis.

Authors:  Swapnil Ulhas Rane; Hasan Mirza; Anita Grigoriadis; Sarah E Pinder
Journal:  Breast Cancer Res Treat       Date:  2015-08-09       Impact factor: 4.872

Review 5.  Progression from ductal carcinoma in situ to invasive breast cancer: revisited.

Authors:  Catherine F Cowell; Britta Weigelt; Rita A Sakr; Charlotte K Y Ng; James Hicks; Tari A King; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2013-07-12       Impact factor: 6.603

6.  PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.

Authors:  Hua Li; Rong Zhu; Lei Wang; Tengfang Zhu; Qiong Li; Qi Chen; Hong Wang; Hongguang Zhu
Journal:  Exp Mol Pathol       Date:  2009-10-08       Impact factor: 3.362

7.  Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Authors:  Lucia Hernandez; Paul M Wilkerson; Maryou B Lambros; Adriana Campion-Flora; Daniel Nava Rodrigues; Arnaud Gauthier; Cecilia Cabral; Vidya Pawar; Alan Mackay; Roger A'Hern; Caterina Marchiò; Jose Palacios; Rachael Natrajan; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2012-03-21       Impact factor: 7.996

8.  Integrative genomics viewer.

Authors:  James T Robinson; Helga Thorvaldsdóttir; Wendy Winckler; Mitchell Guttman; Eric S Lander; Gad Getz; Jill P Mesirov
Journal:  Nat Biotechnol       Date:  2011-01       Impact factor: 54.908

9.  Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.

Authors:  F Wärnberg; H Nordgren; L Bergkvist; L Holmberg
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

10.  Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.

Authors:  S C Doebar; N M Krol; R van Marion; R W W Brouwer; W F J van Ijcken; J M Martens; W N M Dinjens; C H M van Deurzen
Journal:  Virchows Arch       Date:  2018-10-04       Impact factor: 4.064

View more
  1 in total

1.  Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.

Authors:  Helga Bergholtz; Surendra Kumar; Fredrik Wärnberg; Torben Lüders; Vessela Kristensen; Therese Sørlie
Journal:  Cancer Rep (Hoboken)       Date:  2020-05-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.